Autres langues Therapix Biosciences Ltd. OTC Markets

Actions

TRPXY

US88339A3023

Produits pharmaceutiques

Temps Différé OTC Markets			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		+27,78%	+53,33%

30/09	SciSparc Ltd. publie ses résultats pour le semestre clos le 30 juin 2026	CI
26/08	SciSparc Ltd. annonce la nomination du professeur Carmel Domshlak au sein de son conseil consultatif scientifique pour l'IA et la cybersécurité, à compter du 1er septembre 2026	CI

Autres langues

08/10	SciSparc: Subsidiary NeuroThera Labs CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture
07/10	SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture
30/09	SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026
23/09	SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
02/09	SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
31/08	SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
26/08	SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
26/08	Scisparc Ltd. Announces Appointment of Prof. Carmel Domshlak to Scientific Advisory Board for Ai and Cybersecurity, Effective September 1, 2026
24/08	SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
19/08	SciSparc : Amendment to Annual Report by Foreign Issuer (Form 20-F/A)
18/08	SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million
18/08	SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
17/08	Neurothera Labs Inc. announced that it has received CAD 5.4 million in funding from SciSparc Ltd.
12/08	SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
05/08	SciSparc Ltd. Initiates Phase Iib Clinical Trial At Yale Child Study Center for Sci-110 for Tourette Syndrome
05/08	SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
31/07	SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
30/07	SciSparc, Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
29/07	Scisparc Ltd. Announces Establishment of Scientific Advisory Board
29/07	SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
27/07	SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
15/07	SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
30/06	Neurothera Labs Inc. announced that it expects to receive CAD 5.00175 million in funding from SciSparc Ltd.
05/06	SciSparc, Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
04/06	SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum